Chicago Partners Investment Group LLC Raises Stock Holdings in Medtronic PLC $MDT

Chicago Partners Investment Group LLC raised its position in shares of Medtronic PLC (NYSE:MDT) by 68.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,785 shares of the medical technology company’s stock after buying an additional 5,591 shares during the period. Chicago Partners Investment Group LLC’s holdings in Medtronic were worth $1,285,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. AXQ Capital LP lifted its position in shares of Medtronic by 25.6% in the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares during the period. GC Wealth Management RIA LLC increased its position in shares of Medtronic by 20.6% during the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock valued at $2,926,000 after buying an additional 5,734 shares during the period. Merit Financial Group LLC raised its stake in Medtronic by 37.5% in the second quarter. Merit Financial Group LLC now owns 57,035 shares of the medical technology company’s stock worth $4,972,000 after buying an additional 15,561 shares in the last quarter. Verdence Capital Advisors LLC lifted its holdings in Medtronic by 22.0% in the second quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after buying an additional 5,296 shares during the period. Finally, World Investment Advisors boosted its position in Medtronic by 1.9% during the 2nd quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock valued at $13,608,000 after acquiring an additional 2,868 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MDT. TD Cowen reissued a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. Truist Financial dropped their target price on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. Fourteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.28.

Medtronic Stock Performance

Shares of Medtronic stock opened at $101.45 on Friday. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The firm’s 50-day moving average is $99.34 and its 200 day moving average is $95.14. The stock has a market cap of $130.06 billion, a price-to-earnings ratio of 27.35, a PEG ratio of 2.64 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the previous year, the company earned $1.26 earnings per share. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).